Fortrea names Anshul Thakral as permanent CEO effective August 4, 2025

Fortrea Holdings Inc.

Anshul Thakral appointed President and CEO, effective August 4, 2025; replaces interim CEO Peter Neupert who remains chairman.
Thakral has over 20 years experience in CRO, pharma, and biotech; Co-founder/CEO of Launch Therapeutics since 2022.
Offer letter includes $1.1M base salary, 150% target bonus, and inducement equity grants of ~$12.5M (RSUs+PSAs) tied to performance.
Thakral also appointed Class III director; his term expires at 2026 annual meeting.
Severance plan amended to include CEO; equity grants outside 2023 Omnibus Incentive Plan (Nasdaq inducement exception).

item 5.02item 7.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed (interim)

Peter M. Neupert

Interim Chief Executive Officer

FTRE · Fortrea Holdings Inc.

Effective: 2025-08-04
Successor: Anshul Thakral
Filed: Jun 11, 2025 23:59 UTC

Mr. Thakral will replace Peter M. Neupert, who has served as Interim Chief Executive Officer since May 13, 2025, although Mr. Neupert will continue to serve as a director of the Company and Chairman of the Board.

Appointed

Anshul Thakral

Class III Director

FTRE · Fortrea Holdings Inc.

Effective: 2025-08-04
Filed: Jun 11, 2025 23:59 UTC

the Board also appointed Mr. Thakral as a Class III director, effective as of the Effective Date

Appointed

Anshul Thakral

President and Chief Executive Officer

FTRE · Fortrea Holdings Inc.

Effective: 2025-08-04
Filed: Jun 11, 2025 23:59 UTC

the Board of Directors of the Company (the “Board”) has appointed Anshul Thakral as President and Chief Executive Officer of the Company, effective upon his start date with the Company on August 4, 2025

Source: SEC EDGAR

accession 0001193125-25-139161

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.